XTAI
6431
Market cap51mUSD
Oct 08, Last price
16.80TWD
1D
-1.18%
1Q
-7.95%
Jan 2017
110.00%
IPO
-47.17%
Name
Kuangli Bio Tech Holdings Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kuangli Photoelectric Technology Co., Ltd. specializes in the production and distribution of cover lens panels tailored for a wide array of electronic devices. These critical components are integrated into numerous products, including protective screens for mobile phones and laptops, cameras, decorative elements, buttons, and touch panels for tablet PCs and other consumer electronics. Additionally, their portfolio encompasses tempered glass, high-definition media players, digital video recorders (DVs), digital cameras, various home appliances, portable media players (MP3/MP4), vehicle recording devices (dashcams), lampshades, and medical instrumentation. The company commenced operations in 2002 and is headquartered in Kunshan, China.
Key people
Xiangyuan Wang
Assistant General Manager of Finance & Accounting, Corporate Governance Officer · since 2024
Guozhong Fang
Chairman of Subsidiary, General Manager of Subsidiary · since 2021
Afang Lin
Chairman of Subsidiary, General Manager of Subsidiary · since 2021
Jing-Xiang Lin
General Manager, Director · since 2025
Qinglian Zhang
General Manager, Director · since 2020
Wenzhang Hong
Deputy General Manager-R&D · since 2021
Kuant-Sung Chen
Chairman of the Board · since 2021
Xiao-Wei Fang
Director
Rong-Zhong Fang
Director · since 2021
Xiangming Fang
Director · since 2023
Min-Zheng Liao
Director · since 2019
Jia-Wei Wang
Chairman of the Board · since 2025
Qinghui Zhang
Director · since 2019
Shih-Fang Chiu
Independent Director · since 2019
Xi-Lin Chiu
Independent Director · since 2025
Independent Director · since 2013
Huixian Wang
Independent Director · since 2019
Jia-Wei Wu
Independent Director · since 2025
Yi-Sheng Yang
Independent Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||